CoChat

Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches

Open access
Mary, Arnaud, Eysert, Fanny, Checler, Frédéric, Chami, Mounia · 2023 · Molecular Psychiatry

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Abstract

Mitochondrial dysfunctions are central players in Alzheimer’s disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01631-6

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Amyloidogenic and non-amyloidogenic processing of APP. The amyloid precursor protein (APP) is synthesized in the endoplasmic reticulum (ER) and passes through the Golgi apparatus where it undergoes several post-translational modifications such as N- and O-glycosylations, sialylations, phosphorylations and sulfatations before reaching the plasma membrane (PM) in its mature form (mAPP). There, APP can be processed into two different pathways. A In physiological conditions, APP mainly follows the non-amyloidogenic pathway (green arrows), where it is cleaved by the α-secretase, producing secreted sAPPα fragment and membrane-anchored APP-CTF-α (C83), which is then cleaved by the γ-secretase generating secreted P3 fragment and APP intracellular domain (AICD) fragment. Under physiological conditions, APP is also marginally processed in the amyloidogenic pathway (red arrows), in which it is first internalized in endosomes and cleaved by the β-secretase generating sAPPβ fragment and membrane-anchored APP-CTF-β (C99). The latter is subsequently cleaved by the γ-secretase to generate Aβ and AICD (APP intracellular domain), or by the α-secretase to generate the C83 peptide. B In Alzheimer’s disease (AD), APP is mostly processed in the amyloidogenic pathway. It also accumulates and is processed in the intracellular compartments including the endoplasmic reticulum (ER) and mitochondria-associated membranes (MAMs), where secretases are also present. Secreted monomeric Aβ1-42 (moAβ1-42) peptide is prone to oligomerize (oAβ1-42) and generates extracellular amyloid plaques.
Fig. 1 Amyloidogenic and non-amyloidogenic processing of APP. The amyloid precursor protein (APP) is synthesized in the endoplasmic reticulum (ER) and passes through the Golgi apparatus where it undergoes several post-translational modifications such as N- and O-glycosylations, sialylations, phosphorylations and sulfatations before reaching the plasma membrane (PM) in its mature form (mAPP). There, APP can be processed into two different pathways. A In physiological conditions, APP mainly follows the non-amyloidogenic pathway (green arrows), where it is cleaved by the α-secretase, producing secreted sAPPα fragment and membrane-anchored APP-CTF-α (C83), which is then cleaved by the γ-secretase generating secreted P3 fragment and APP intracellular domain (AICD) fragment. Under physiological conditions, APP is also marginally processed in the amyloidogenic pathway (red arrows), in which it is first internalized in endosomes and cleaved by the β-secretase generating sAPPβ fragment and membrane-anchored APP-CTF-β (C99). The latter is subsequently cleaved by the γ-secretase to generate Aβ and AICD (APP intracellular domain), or by the α-secretase to generate the C83 peptide. B In Alzheimer’s disease (AD), APP is mostly processed in the amyloidogenic pathway. It also accumulates and is processed in the intracellular compartments including the endoplasmic reticulum (ER) and mitochondria-associated membranes (MAMs), where secretases are also present. Secreted monomeric Aβ1-42 (moAβ1-42) peptide is prone to oligomerize (oAβ1-42) and generates extracellular amyloid plaques.CC BY · PubMed Central
Fig. 2 Physiological mitophagy processes and alterations linked to Tau, Aβ, APP-CTFs and APOE. A Following mitochondrial stress (i.e., mitochondria membrane (ΔΨmit) depolarization, or a general cellular stress (i.e. hypoxia, ischemia, starvation)), mitochondria undergo a specific degradation mechanism by mitophagy. The PINK1/Parkin-dependent mitophagy is driven by a decrease of ∆Ψmit, triggering the stabilization of PTEN-induced putative kinase 1 (PINK1) at the OMM and the recruitment of the E3 Ubiquitin ligase Parkin, generating poly-phospho-ubiquitinated chains (p-S65-Ub) on OMM proteins that act as a “eat-me” signal for damaged mitochondria. Cytosolic proteins that can act as mitophagy receptors (p62, OPTN, NDP52, NBR1, or TAX1BP1) will recognize and bind to p-S65-Ub decorated proteins and will recruit the phagosome through their interaction, via their LIR motif with LC3-II (the activated form of the microtubule-associated protein 1 A/1B light chain 3) present at the surface of the phagosome. Besides, in the PINK1/Parkin-independent mitophagy, the phagosome is recruited around mitochondria directly through LIR motif-containing OMM receptors (NIX/BNIP3L, BNIP3, FUNDC1, BCL2L13, FKBP8, DISC1, AMBRA1, or MCL-1) or through the recognition of cardiolipin (CL) exposed on the OMM. Once the phagophore is recruited, it engulfs damaged mitochondria to generate the mitophagosome. Then, lysosomes can fuse with mitophagosomes to form mitolysosomes and degrade damaged mitochondria by acidic hydrolases. B–E Mitophagic process is perturbed in AD by Tau species (B), Aβ species (C). APP-CTFs (D), and APOE4 isoform and/or high cholesterol levels (E). Proteins that are impacted in the mitophagy process are depicted in grey in (B–E) instead of being colored as in (A). Inhibitory functions are indicated by red arrows, and green arrows indicate PINK1/Parkin activation and phagophore formation or recruitment.
Fig. 2 Physiological mitophagy processes and alterations linked to Tau, Aβ, APP-CTFs and APOE. A Following mitochondrial stress (i.e., mitochondria membrane (ΔΨmit) depolarization, or a general cellular stress (i.e. hypoxia, ischemia, starvation)), mitochondria undergo a specific degradation mechanism by mitophagy. The PINK1/Parkin-dependent mitophagy is driven by a decrease of ∆Ψmit, triggering the stabilization of PTEN-induced putative kinase 1 (PINK1) at the OMM and the recruitment of the E3 Ubiquitin ligase Parkin, generating poly-phospho-ubiquitinated chains (p-S65-Ub) on OMM proteins that act as a “eat-me” signal for damaged mitochondria. Cytosolic proteins that can act as mitophagy receptors (p62, OPTN, NDP52, NBR1, or TAX1BP1) will recognize and bind to p-S65-Ub decorated proteins and will recruit the phagosome through their interaction, via their LIR motif with LC3-II (the activated form of the microtubule-associated protein 1 A/1B light chain 3) present at the surface of the phagosome. Besides, in the PINK1/Parkin-independent mitophagy, the phagosome is recruited around mitochondria directly through LIR motif-containing OMM receptors (NIX/BNIP3L, BNIP3, FUNDC1, BCL2L13, FKBP8, DISC1, AMBRA1, or MCL-1) or through the recognition of cardiolipin (CL) exposed on the OMM. Once the phagophore is recruited, it engulfs damaged mitochondria to generate the mitophagosome. Then, lysosomes can fuse with mitophagosomes to form mitolysosomes and degrade damaged mitochondria by acidic hydrolases. B–E Mitophagic process is perturbed in AD by Tau species (B), Aβ species (C). APP-CTFs (D), and APOE4 isoform and/or high cholesterol levels (E). Proteins that are impacted in the mitophagy process are depicted in grey in (B–E) instead of being colored as in (A). Inhibitory functions are indicated by red arrows, and green arrows indicate PINK1/Parkin activation and phagophore formation or recruitment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Cited by

See all 244

Metadata

Authors
Mary, A., Eysert, F., Checler, F., & Chami, M.
Affiliations
Centre National de la Recherche Scientifique (FR)
Corresponding author
Chami, Mounia
Venue
Molecular Psychiatry
Published
2022-06-03
Volume
28
Issue
1
Pages
202-216
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4281929193
Cited by
244
References
113
Citations by year
2026: 56 · 2025: 92 · 2024: 55 · 2023: 34 · 2022: 7
FWCI
7.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
Funders
  • Fondation Vaincre Alzheimer
  • LABEX (excellence laboratory, program investment for the future) DISTALZ
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
mitophagy, Alzheimer's disease, mitochondrial dysfunction, autophagy, tau protein, amyloid-beta, apolipoprotein E, treatment options, clinical trials
MeSH terms
Alzheimer Disease, Animals, Autophagy, Disease Models, Animal, Humans, Mitochondria, Amyloid beta-Peptides, Mitophagy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. https://app.cochat.ai/papers/10.1038/s41380-022-01631-6
The paper
Mary, A., Eysert, F., Checler, F., & Chami, M. (2023). Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01631-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.